Cognition Therapeutics Presents Complete EEG Findings from SEQUEL Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease at CTAD
24 Octubre 2023 - 3:30PM
Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or
“Cognition”) announced that Willem de Haan, M.D., Ph.D., a
neurologist and senior researcher at the Amsterdam University
Medical Centers’ Alzheimer Center, is presenting complete EEG
findings from the Phase 2 SEQUEL study at the Clinical Trials on
Alzheimer’s Disease (CTAD) conference. SEQUEL was conducted at the
Amsterdam UMC in the Netherlands with Everard (Jort) Vijverberg,
M.D., Ph.D., acting as principal investigator. The poster
describing changes in brain wave patterns in adults with
mild-to-moderate Alzheimer’s disease following 28-days of treatment
with CT1812 or placebo will be on display through the conclusion of
CTAD.
In the SEQUEL study, CT1812-treated participants exhibited a
statistically significant change in relative theta in the central
region of the brain and consistent trends of improvement across all
prespecified EEG parameters. In particular, improvements were seen
in global relative theta power (p=0.123) and in global relative
alpha power (p=0.149), as well as in connectivity, as assessed by
alpha AECc (p=0.034), which may indicate improved communication
between different parts of the brain.
Synaptic dysfunction is observed early in the Alzheimer’s
disease process and is correlated with subsequent cognitive
decline. There is substantial evidence to believe that quantitative
electroencephalography (qEEG) can be used to measure this decline
of electrical activity in the brain. In Alzheimer’s disease,
cognitive decline is associated with increasing prominence of
slower EEG frequencies (4-8 Hz) termed “theta” and a declining
prominence of “alpha” frequencies (8-12 Hz), which are the dominant
brainwaves in cognitively normal individuals. The measures of
connectivity between regions of the brain are believed to be as
critical as regional measures of brain activity when assessing
disease.
“CT1812 treatment showed improvement of EEG parameters that are
consistent in magnitude and effect size with previously reported
trials,” explained Dr. de Haan. “Notably, these positive changes
occurred after only a short treatment interval. To see this
measurable result in a matter of weeks in individuals with
mild-to-moderate disease is exciting and provides optimism that
CT1812 is altering underlying Alzheimer’s disease processes.”
The poster being presented by Dr. de Hann will be available on
the Cognition Therapeutics website along with additional content
relevant to the company’s CTAD presentations at
https://cogrx.com/ctad2023.
About CT1812CT1812 is an experimental orally
delivered small molecule sigma-2 (σ-2) receptor modulator designed
to penetrate the blood-retinal barrier and bind selectively and
saturably to the σ-2 receptor complex. The σ-2 receptor complex is
involved in the regulation of key cellular processes such as
membrane trafficking and autophagy that are damaged by toxic
interaction with soluble beta amyloid (Aβ) oligomers, oxidative
stress and other stressors. Cognition’s clinical program will
assess if regulating these processes by modulating the σ-2 receptor
with CT1812 can maintain homeostatic function.
About the SEQUEL StudyThe SEQUEL study enrolled
16 adults with mild-to-moderate Alzheimer’s disease (MMSE 18-26),
each of whom were randomized to receive either CT1812 or placebo
once daily for 28 days. After a 14-day wash-out period,
participants cross over into the other treatment arm for an
additional 28 days. SEQUEL was designed to assess the safety and
efficacy of CT1812 and to measure the impact of CT1812 on the
electrical activity in the brain, specifically those electrical
impulses in the theta band.
SEQUEL was supported by $5.3 million in grant awards
(R01AG058710) by the National Institute of Aging (NIA) of the
National Institutes of Health (NIH).
About Cognition Therapeutics, Inc.Cognition
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of innovative, small
molecule therapeutics targeting age-related degenerative disorders
of the central nervous system and retina. We are currently
investigating our lead candidate CT1812 in clinical programs in
Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry
age-related macular degeneration (dry AMD). We believe CT1812 and
our pipeline of σ-2 receptor modulators can regulate pathways that
are impaired in these diseases. We believe that targeting the σ-2
receptor with CT1812 represents a mechanism functionally distinct
from other current approaches in clinical development for the
treatment of degenerative diseases. More about Cognition
Therapeutics and its pipeline can be found
at https://cogrx.com
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release, other than statements of
historical facts or statements that relate to present facts or
current conditions, including but not limited to, statements
regarding our product candidates, including CT1812, and any
expected or implied benefits or results, including that initial
clinical results observed with respect to CT1812 will be replicated
in later trials and our clinical development plans, are
forward-looking statements. These statements, including statements
relating to the timing and expected results of our clinical trials
involve known and unknown risks, uncertainties and other important
factors that may cause our actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” “might,” “will,”
“should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “forecast,” “potential” or “continue” or the
negative of these terms or other similar expressions. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: competition; our ability to secure new (and retain existing)
grant funding; our ability to grow and manage growth, maintain
relationships with suppliers and retain our management and key
employees; our ability to successfully advance our current and
future product candidates through development activities,
preclinical studies and clinical trials and costs related thereto;
uncertainties inherent in the results of preliminary data,
pre-clinical studies and earlier-stage clinical trials being
predictive of the results of early or later-stage clinical trials;
the timing, scope and likelihood of regulatory filings and
approvals, including regulatory approval of our product candidates;
changes in applicable laws or regulations; the possibility that the
we may be adversely affected by other economic, business or
competitive factors, including ongoing economic uncertainty; our
estimates of expenses and profitability; the evolution of the
markets in which we compete; our ability to implement our strategic
initiatives and continue to innovate our existing products; our
ability to defend our intellectual property; the impact of the
COVID-19 pandemic on our business, supply chain and labor force;
and the risks and uncertainties described more fully in the “Risk
Factors” section of our annual and quarterly reports filed with
the Securities Exchange Commission and are available at
www.sec.gov. These risks are not exhaustive and we face both known
and unknown risks. You should not rely on these forward-looking
statements as predictions of future events. The events and
circumstances reflected in our forward-looking statements may not
be achieved or occur, and actual results could differ materially
from those projected in the forward-looking statements. Moreover,
we operate in a dynamic industry and economy. New risk factors and
uncertainties may emerge from time to time, and it is not possible
for management to predict all risk factors and uncertainties that
we may face. Except as required by applicable law, we do not plan
to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.
Contact Information:Cognition Therapeutics,
Inc.info@cogrx.com |
Casey McDonald (media)Tiberend Strategic Advisors,
Inc.cmcdonald@tiberend.com |
Daniel Kontoh-Boateng (investors) Tiberend Strategic
Advisors, Inc. dboateng@tiberend.com |
Cognition Therapeutics (NASDAQ:CGTX)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Cognition Therapeutics (NASDAQ:CGTX)
Gráfica de Acción Histórica
De May 2023 a May 2024